Journal issues > Issue 8, December 2022 > Coombs-negative haemolysis in hepatosplenic T-cell lymphoma

Coombs-negative haemolysis in hepatosplenic T-cell lymphoma

By: R.L. van der Horst MD, R.L. Römers MD, F. Stifft MD, R.J. Martens MD, M.P. Leers MD, R.J. van Kampen MD

SUMMARY

We present to you a Coombs-negative haemolytic anaemia in a patient with a hepatosplenic T-cell lymphoma (HSTL). The underlying mechanism was considered to be due to the massive hypersplenism or a Coombs negative immune-mediated direct cytotoxic mechanism, which has been previously described in patients with HSTL. Our patient was treated with cytostatic therapy consisting of dexamethasone, cytarabin and cisplatin (DHAP), followed by allogenic stem cell transplantation, after which complete remission was achieved.

(BELG J HEMATOL 2022;13(8):316–20)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top